Can brain amyloid reduction be used as a surrogate biomarker of clinical benefit? This is a hotly debated question in the field (see Dec 2024 discussion). A recent post hoc analysis of Phase 3 ...

Biogen and Denali yesterday announced they will stop development of the LRRK2 kinase inhibitor DNL151 for sporadic Parkinson’s disease. Top-line data from the LUMA Phase 2b trial indicated that the ...

The family tree of tau filament folds continues to sprout new branches. With them come new questions. At the Tau Global Conference, held May 14-15 in Washington, D.C., scientists grappled with the ...

Are efforts to target tau finally starting to pay off? Just a little, maybe? The Tau Global Conference, held in Washington, D.C., May 14 to 15, showcased recent progress in basic science, biomarkers, ...

Can PI-2620 track progressive supranuclear palsy (PSP)? Scientists led by Matthias Brendel at Ludwig Maximilian University, Munich, have found that the tracer captures tau accumulation in several ...

Lu AF87908 is a humanized mouse IgG1 monoclonal antibody to phosphorylated tau protein. It was generated by immunization of mice with a tau peptide spanning residues 386-408 and phosphorylated at ...

Contact Information Brian Spencer, Ph.D. San Diego, United States Professional Information Assistant ProfessorUniversity of Southern California ...

At the Tau Global conference, speakers showcased progress in an antisense oligonucleotide and a small-molecule p75 modulator. Other strategies also look promising.

Score another one for amyloid immunotherapy. The anti-pyroglutamated amyloid antibody donanemab has posted positive top-line results in the Phase 3 Trailblazer-Alz2 study, according to an Eli Lilly ...

It has been clear for a while that anti-amyloid antibodies can sweep plaque from the brain, but until now the question of whether this slows cognitive decline has remained hotly contended. Despite ...

This database is a repository of normal genetic variability, designed to be a tool for researchers who study neurodegenerative disease. It contains whole-exome sequencing results from nearly 500 ...

Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...